ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
Last month, Representative Diana DeGette (D-CO) and Senator Brian Schatz (D-HI) introduced companion bills (H.R. 2411/S. 1258) in the House and Senate to raise the legal age of purchasing tobacco to 21. ASCO has endorsed this legislation as a part of its ongoing commitment to policies that reduced the prevalence of tobacco use and occurrence of cancer and other smoking-caused diseases.
ASCO and Friends of Cancer Research have commended the U.S. Food and Drug Administration on four recently released draft guidance documents related to expanding clinical trial eligibility in a joint letter to Acting Commissioner Ned Sharpless, MD.
CancerLinQ LLC and the International Association for the Study of Lung Cancer (IASLC) have announced a collaboration to expand the specialized expertise informing CancerLinQ®, a health information technology platform, developed by oncologists for oncologists, to enhance and improve the understanding and treatment of cancer. The IASLC will contribute thought leadership and subject matter expertise to CancerLinQ including aspects of clinical practice related to the diagnosis and management of lung cancer, the identification and development of clinical quality measures for thoracic oncology, and other relevant content.
Today, the American Society of Clinical Oncology (ASCO) and the American Cancer Society Cancer Action Network (ACS CAN) hosted a joint reception on Capitol Hill for Members of Congress to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and cancer survivors.
Early registration is now open for the ASCO Research Community Forum (RCF) 2019 Annual Meeting. The ASCO RCF Annual Meeting brings together physician investigators and research staff from across the country for two days of learning and collaboration. The meeting offers colleagues from a variety of types of research programs a unique platform to collaborate and develop solutions to common challenges with conducting oncology clinical trials.
Hospital Universitario Central De Asturias - Medical Oncology Service has become the fifth practice in Spain to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC, and the eleventh practice internationally to receive this accreditation.
On May 3, 2019, the Food and Drug Administration approved ado-trastuzumab emtansine (KADCYLA®, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO®, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.
In an effort to understand how oncology providers are assessing older adults with cancer, ASCO is conducting a 5-minute survey among oncology providers about if, when, and how they obtain and interpret geriatric assessment findings and incorporate the findings into the cancer treatment decision-making process.
Mathematics, modeling, and simulation to study cancer are topics covered in a new special series in JCO Clinical Cancer Informatics (JCO CCI).
ASCO commends the 24 practices that took their standard of care to the next level and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year.
As part of ASCO’s State of Cancer Care in America™ initiative, the Journal of Oncology Practice published an infographic about opioids and cancer pain, which highlights the specific needs of patients with cancer and some of the hurdles they face in trying to access prescribed opioids to manage cancer-related pain.
Earlier this month, ASCO’s Quality Training Program held its first sessions in Romania and Greece, with a local practice in each location hosting the program’s one-day workshop.
On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA®, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).